CNS PharmaceuticalsCNS PharmaceuticalsCNS Pharmaceuticals
  • Brain
    • Glioblastoma
    • Anthracyclines
    • Blood Brain Barrier
  • Technology
    • Berubicin
    • Pipeline
  • Team
    • Management
    • Board
  • About Us
  • Contact
  • Investors
  • Sign Up

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Analyst Coverage
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin for Phase 2 Clinical Trial

Oct 20, 2020 8:00am EDT

CNS Pharmaceuticals Highlights New Balancing Act Segment on Glioblastoma Airing on Lifetime TV

Oct 12, 2020 8:00am EDT

CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe

Oct 09, 2020 8:00am EDT

CNS Pharmaceuticals Achieves Critical Manufacturing Milestone

Oct 01, 2020 8:00am EDT

CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin

Sep 24, 2020 8:00am EDT

CNS Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Sep 17, 2020 8:00am EDT

CNS Pharmaceuticals to Present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

Sep 11, 2020 8:00am EDT

CNS Pharmaceuticals Announces US Drug Manufacturing Milestones

Sep 03, 2020 8:00am EDT

CNS Pharmaceuticals Announces Appointment of Dr. Patrick Wen, Director of Center for Neuro-Oncology at Dana-Farber Cancer Institute, to Science Advisory Board

Aug 27, 2020 8:00am EDT

CNS Provides FDA Update on IND Filing

Aug 25, 2020 8:39am EDT
RSS
  • Prev
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    © 2023 CNS Pharmaceuticals. All Rights Reserved, CNS Pharma

    • Brain
      • Glioblastoma
      • Anthracyclines
      • Blood Brain Barrier
    • Technology
      • Berubicin
      • Pipeline
    • Team
      • Management
      • Board
    • About Us
    • Contact
    • Investors
    • Sign Up